Tandem: Using AI to Automate Prescription Paperwork, Hits $1B Valuation

New York-based healthtech startup Tandem has reached a $1 billion valuation after raising about $100 million in a Series B round, according to people familiar with the matter. The round is reported to be led by Accel as the company scales its artificial intelligence solution for prescription workflows.

Tandem’s product automates the administrative tasks that often stall prescriptions—prior authorization submissions, appeals and routing to the patient’s preferred pharmacy—offering the service free to providers and patients while monetizing through partnerships and enterprise contracts. Reporting indicates the company has previously attracted investment from firms including General Catalyst and Thrive Capital, and has raised roughly $137 million to date.

The startup’s emergence highlights a persistent industry problem: administrative friction in prescription fulfillment creates significant costs and contributes to prescriptions going unfilled, which can delay or interrupt patient care. Industry analyses and pharmacy trade literature estimate that prior authorization and related paperwork impose billions in annual administrative burdens on clinicians and the health system. Tandem’s automation aims to reduce those frictions and speed patient access to medicines.

From a market perspective, investors are watching whether prescription workflow automation can translate into durable revenue and margin expansion. Tandem’s pathway to scale appears to hinge on deep integrations with electronic health record systems, pharmacy benefit managers and biopharma partners that can use streamlined workflows for trial drug distribution or patient support programs. Bloomberg reports the company’s explicit ambition to partner across the drug supply chain to broaden adoption.

Analysts caution that growth will depend on regulatory compliance, data security, and measurable clinical and financial outcomes. If Tandem proves it can materially cut approval times and administrative cost per prescription, the company could become a strategic vendor for providers, payers and manufacturers—potentially justifying its current valuation and supporting larger rounds or strategic exits in the coming years.